---
title: 'Funding Daily Summary: What Happened on October 27, 2026'
headline: Atlas Bio launches with $12.5 million for drug-response simulations
description: The company says its AI platform uses human-tissue data to model how
  patients may respond to treatments.
url: https://thebench.bio/news/funding/2026-10-27
topic: funding
date: '2026-10-27'
covers:
- '2026-10-27'
date_published: '2026-10-28T00:02:05Z'
date_modified: '2026-10-28T00:02:05Z'
tags:
- Clinical
sources: 1
publisher: TheBench.Bio
---

# Funding Daily Summary: What Happened on October 27, 2026

**Atlas Bio launches with $12.5 million for drug-response simulations**

The company says its AI platform uses human-tissue data to model how patients may respond to treatments.

## Today in brief

Atlas Bio emerged from stealth with $12.5 million to develop AI-based drug-response simulations. [1]

## Funding and platform

Atlas Bio disclosed a $10 million seed round led by Creandum and a $2.5 million pre-seed round led by First Momentum Ventures and LEA Partners. [1] The company says it will use the funding for scientific and commercial hiring, platform validation and gaining more enterprise customers. [1]

Atlas Bio says its model learned from about 2 million human-tissue RNA readouts and estimates how patient profiles may respond to treatments. [1]

## Sources

1. [Atlas Bio launches with $12.5M to eliminate animal testing and simulate Phase 2 trials](<https://european-biotechnology.com/latest-news/atlas-bio-launches-with-12-5m-to-eliminate-animal-testing-and-simulate-phase-2-trials/>), European Biotechnology, 2026-10-27

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://european-biotechnology.com/latest-news/atlas-bio-launches-with-12-5m-to-eliminate-animal-testing-and-simulate-phase-2-trials/>